Pegcetacoplan – July 2026

  • Brand names:
    • Empaveli®
  • Pharmaceutical Company:
    • SWEDISH ORPHAN BIOVITRUM PTY LTD
  • Condition/Indication: Complement 3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN)
  • Meeting Date: July 2026
Public Summary Documents
Last updated
13 November 2026